Developing treatments for ALS by targeting a specific protein called STAU1
Targeting STAU1 for TDP-43 proteinopathies
This study is testing a new treatment that uses special molecules to lower a protein called STAU1, which is linked to ALS, with the hope of improving symptoms and helping people with ALS feel better and move more easily.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10732627 on NIH RePORTER |
What this research studies
This research focuses on creating antisense oligonucleotides (ASOs) that target the STAU1 protein, which is linked to neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). By reducing the levels of STAU1, the researchers aim to modify disease-related symptoms and improve motor function in ALS patients. The study builds on previous findings that lowering STAU1 can lead to positive changes in disease models, and it involves optimizing the ASO sequences for effective treatment. Patients may benefit from this innovative approach if the treatments prove successful in clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with amyotrophic lateral sclerosis (ALS) who may benefit from novel therapeutic approaches.
Not a fit: Patients with other neurodegenerative disorders not related to TDP-43 proteinopathies may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly improve the quality of life for ALS patients.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for neurodegenerative diseases, indicating potential for success in this novel approach.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Scoles, Daniel R — University of Utah
- Study coordinator: Scoles, Daniel R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.